Nektar Therapeutics has filed a patent for conjugates that involve attaching a water-soluble polymer to a Factor VIII moiety through an oxime-containing linkage. The patent also covers methods for preparing and administering these conjugates, as well as the use of water-soluble polymer oxyamine reagents in their production. GlobalData’s report on Nektar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nektar Therapeutics - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nektar Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Nektar Therapeutics's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230241181A1) describes a conjugate that consists of a water-soluble polymer covalently attached to an oxidized carbohydrate of a Factor VIII moiety through an oxime-containing linkage. The structure of the conjugate is described as POLY-X—O—N-CH-FVIII, where POLY represents the water-soluble polymer, X is an optional spacer, and FVIII is the Factor VIII moiety. The optional spacer, X, is hydrolytically stable and may contain heteratoms such as O, S, and NH. The atom chain length of X ranges from about 5 atoms to about 25 atoms.

The water-soluble polymer in the conjugate is specified as a poly(alkylene oxide) and has a weight-average molecular weight ranging from 2,000 daltons to 85,000 daltons. Another structure of the conjugate is described as CH3O—CH2CH2O—(CH2CH2O)m'—CH2CH2—O—NH-CH-(FVIII), where (m') can range from zero to about 4,000. The Factor VIII moiety in the conjugate can be either human recombinant B-domain deleted Factor VIII or human recombinant full-length Factor VIII.

The patent also covers a composition comprising the conjugate and a pharmaceutically acceptable excipient. This composition can be used for treating patients with hemophilia A. Additionally, a polymeric oxyamine reagent is described in the patent, which has various structures depending on the X component. The X component can be or comprise —NH(CH2)1-6—, —NH(CH2)2—, or —NH(CH2)1-6NHC(O)CH2—.

In summary, the patent describes a conjugate consisting of a water-soluble polymer attached to an oxidized carbohydrate of a Factor VIII moiety through an oxime-containing linkage. The patent also covers the composition comprising this conjugate for the treatment of hemophilia A. The patent further discloses a polymeric oxyamine reagent with different structures based on the X component.

To know more about GlobalData’s detailed insights on Nektar Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies